This study will evaluate the efficacy and safety of adjuvant therapy with liposomal irinotecan in combination with oxaliplatin, and S-1 compared with capecitabine combined with capecitabine in participants with pancreatic ductal adenocarcinoma after radical surgery.
Patients able and willing to provide a written informed consent aged 18-75 years.
Histologically confirmed resected ductal pancreatic adenocarcinoma (including adenosquamous carcinoma).
Undergone radical resection and confirmed macroscopic complete resection (R0 and R1).
Full recovery after surgery; able to start adjuvant treatment within 12 weeks after surgery.
Patients with other types of non-ductal tumor of the pancreas, including endocrine tumors or acinar cell adenocarcinoma, pancreatoblastoma, and solid-pseudopapillary tumor.
Macroscopic incomplete tumor removal (R2 resection).
Prior neo-adjuvant treatment, radiation therapy, or systemic therapy for pancreatic adenocarcinoma.
Presence or history of metastatic or locally recurrent pancreatic adenocarcinoma.